Renin & Angiotensin II: Renal Perfusion, Filtration Pressure & Systemic Vasoconstriction
The renin–angiotensin system (RAS) is one of the most powerful regulatory mechanisms in the human body, integrating renal function with blood pressure, circulatory volume, and sodium balance. While aldosterone determines long-term sodium retention and ADH regulates water balance, renin and angiotensin II provide the critical upstream control that determines how the kidneys interpret and respond to changes in perfusion pressure. This system allows the kidneys to maintain glomerular filtration even during dramatic shifts in systemic blood pressure, such as dehydration, haemorrhage, or shock. Without the RAS, blood pressure would collapse rapidly during fluid loss, and the kidneys would lose their ability to filter the blood.
What You Need to Know
Renin is an enzyme released by the juxtaglomerular cells of the kidney in response to signals that indicate falling renal perfusion or threatened filtration. These signals include decreased pressure in the afferent arteriole, reduced sodium delivery to the macula densa, and activation of the sympathetic nervous system. Together, they allow the kidney to act as a pressure and volume sensor, triggering renin release when blood flow or circulating volume is inadequate.
Once renin is released, it initiates the renin–angiotensin cascade, leading to the formation of angiotensin II. Angiotensin II is a powerful hormone that coordinates vascular tone, kidney function, and fluid balance by:
constricting blood vessels throughout the body to raise systemic blood pressure
preferentially constricting the efferent arteriole in the kidney to maintain glomerular filtration pressure
stimulating aldosterone release to promote sodium and water retention
enhancing thirst and antidiuretic hormone release to support volume restoration
Through these combined actions, angiotensin II allows the kidneys to defend filtration even when overall blood pressure is low.
By linking renal blood flow to systemic vascular and volume regulation, the renin–angiotensin system forms one of the body’s most important blood pressure control mechanisms. It ensures that when circulation is threatened, the kidneys can preserve their own function while simultaneously helping to stabilise perfusion of vital organs.
Beyond the Basics
The Juxtaglomerular Apparatus & Renin Release
The juxtaglomerular apparatus sits at a strategic anatomical junction where the distal convoluted tubule loops back to contact the afferent and efferent arterioles of the same nephron. This positioning allows the kidney to directly compare how much blood is arriving at the glomerulus with how much filtrate is leaving it. It is composed of three specialised cell types: the macula densa, the juxtaglomerular (JG) cells, and extraglomerular mesangial cells, which together form a local sensing and signalling unit.
JG cells are modified smooth muscle cells in the wall of the afferent arteriole that act as intrarenal baroreceptors. When renal perfusion pressure falls, the arteriole stretches less, and this mechanical change is detected by the JG cells, triggering the release of renin. This allows the kidney to directly translate reduced blood pressure into a hormonal response that attempts to restore it.
The macula densa, located in the distal tubule, monitors the sodium chloride concentration of the tubular fluid. Because sodium delivery reflects how much filtration has occurred upstream, low NaCl at the macula densa signals reduced glomerular filtration or reduced effective circulating volume. In response, the macula densa sends paracrine signals to nearby JG cells, reinforcing renin release. This creates a feedback loop that links tubular flow to vascular control.
Sympathetic nervous system input provides a third control pathway. During stress, trauma, haemorrhage, or shock, β₁-adrenergic stimulation directly activates JG cells, ensuring renin is released even before major drops in filtration occur. Together, these three inputs allow the kidney to act as both a pressure sensor and a volume sensor, responding rapidly to any threat to renal perfusion.
The Renin–Angiotensin Cascade
Once released into the circulation, renin begins a biochemical cascade that amplifies a local kidney signal into a body-wide response. Renin cleaves angiotensinogen, a plasma protein produced continuously by the liver, to form angiotensin I. This initial step is rate-limiting, meaning that the amount of renin released determines how strongly the system is activated.
Angiotensin I is then converted into angiotensin II by angiotensin-converting enzyme (ACE), which is highly expressed on the endothelial surface of pulmonary capillaries. This anatomical arrangement ensures that nearly all angiotensin I passing through the lungs is rapidly converted into the active hormone angiotensin II before entering the systemic circulation.
Angiotensin II acts as the central effector of the system, translating a drop in renal perfusion into coordinated vascular, renal, and hormonal responses designed to restore blood pressure and circulating volume.
Angiotensin II: Systemic & Renal Effects
Angiotensin II is one of the most powerful endogenous regulators of circulation and kidney function. Its effects are wide-ranging but tightly coordinated.
Potent systemic vasoconstriction
Angiotensin II constricts arterioles throughout the body, increasing total peripheral resistance and raising arterial blood pressure. This helps redirect blood toward vital organs such as the brain, heart, and kidneys during volume loss or shock.
Preferential efferent arteriole constriction
Within the kidney, angiotensin II constricts both the afferent and efferent arterioles, but it acts more strongly on the efferent arteriole. This increases pressure inside the glomerular capillaries, allowing filtration to continue even when overall renal blood flow is reduced. This mechanism protects GFR during hypotension, although prolonged activation can increase stress on the glomerulus.
Enhanced sodium reabsorption in the proximal tubule
Angiotensin II directly stimulates sodium–hydrogen exchange in the proximal tubule. This increases sodium and water reabsorption early in the nephron, helping expand circulating volume even before aldosterone takes effect.
Stimulation of aldosterone secretion
By acting on the adrenal cortex, angiotensin II triggers aldosterone release. Aldosterone increases sodium reabsorption and potassium excretion in the distal nephron, reinforcing volume expansion and long-term blood pressure regulation.
Stimulation of thirst and ADH release
Angiotensin II also acts on the brain to increase thirst and promote antidiuretic hormone release. This encourages fluid intake and reduces water loss, further stabilising plasma volume.
RAS as a Multi-Level Defence Against Hypotension
The renin–angiotensin system operates across multiple time scales, allowing the body to respond both rapidly and sustainably to low blood pressure or volume loss:
Immediate response: systemic vasoconstriction raises blood pressure
Short-term response: efferent arteriole constriction preserves glomerular filtration
Intermediate response: increased proximal sodium and water reabsorption
Long-term response: aldosterone-mediated volume expansion
Parallel response: thirst and ADH promote water intake and retention
These layers allow the kidneys not only to defend their own filtration but also to stabilise the entire circulatory system during dehydration, bleeding, or shock.
Clinical Connections
Overactivation of the renin–angiotensin system (RAS) plays a central role in many cardiovascular and renal diseases. Chronic elevation of angiotensin II leads to sustained vasoconstriction, sodium retention, and increased glomerular pressure. Over time, this intraglomerular hypertension damages the filtration barrier, promoting proteinuria and accelerating nephron loss, which contributes to the progression of chronic kidney disease and diabetic nephropathy.
There are multiple pharmacological agents which target RAAS to influence blood blood pressure. ACE inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors reduce angiotensin II–mediated effects, leading to:
lower systemic blood pressure
reduced efferent arteriole constriction
decreased glomerular pressure and protein leakage
slower progression of chronic kidney disease
These protective effects explain why RAS blockade is first-line therapy in hypertension, heart failure, and proteinuric kidney disease.
However, the same mechanisms that make RAS blockade beneficial can become dangerous when renal perfusion is already compromised. In conditions such as bilateral renal artery stenosis, severe dehydration, or shock, angiotensin II is required to maintain glomerular filtration by constricting the efferent arteriole. Blocking this response can cause a sudden fall in GFR and precipitate acute kidney injury.
RAS activation is therefore highly context dependent. In acute volume loss such as haemorrhage or dehydration, it is life-saving, preserving blood pressure and kidney filtration. In contrast, in heart failure or cirrhosis, reduced effective arterial volume triggers inappropriate RAS activation, leading to sodium and water retention, oedema, and further circulatory strain. Understanding this balance allows clinicians to predict when RAS should be supported and when it must be suppressed.
Concept Check
Why does the kidney preferentially constrict the efferent arteriole in response to angiotensin II?
How does the macula densa regulate renin release in response to tubular fluid composition?
Why does angiotensin II stimulate both aldosterone and ADH release?
Why can ACE inhibitors reduce GFR in patients with renal artery stenosis?
How does angiotensin II simultaneously support short-term and long-term blood pressure control?